A phase 1/1B trial of ADI ‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma

CONCLUSIONSADI‐PEG 20 was well tolerated in combination with gemcitabine and nab‐paclitaxel. Activity was observed in previously treated and untreated patients with advanced pancreatic cancer and in patients with ASS1‐deficient and ‐proficient tumors. Cancer 2017. © 2017 American Cancer Society.

Source: Cancer - August 18, 2017 Category: Cancer & Oncology Authors: Maeve A. Lowery, Kenneth H. Yu, David Paul Kelsen, James J. Harding, John S. Bomalaski, Danielle C. Glassman, Christina M. Covington, Robin Brenner, Ellen Hollywood, Adalberto Barba, Amanda Johnston, Kay Chia ‐Wei Liu, Xiaoxing Feng, Marinela Capanu, Gh Tags: Original Article Source Type: research